tradingkey.logo

Xtant Medical Holdings Inc

XTNT

0.561USD

+0.001+0.14%
Market hours ETQuotes delayed by 15 min
78.00MMarket Cap
LossP/E TTM

Xtant Medical Holdings Inc

0.561

+0.001+0.14%
More Details of Xtant Medical Holdings Inc Company
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
Company Info
Ticker SymbolXTNT
Company nameXtant Medical Holdings Inc
IPO dateJun 30, 2010
CEOMr. Sean E. Browne
Number of employees217
Security typeOrdinary Share
Fiscal year-endJun 30
Address664 Cruiser Lane
CityBELGRADE
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code59714
Phone14063880480
Websitehttps://xtantmedical.com/
Ticker SymbolXTNT
IPO dateJun 30, 2010
CEOMr. Sean E. Browne
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
6.21M
-7.87%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
593.73K
-2.78%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Kevin D. Brandt
Mr. Kevin D. Brandt
Chief Commercial Officer
Chief Commercial Officer
337.88K
+49.10%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
234.31K
-4.39%
Ms. Lori Mitchell-Keller
Ms. Lori Mitchell-Keller
Independent Director
Independent Director
190.96K
-8.17%
Mr. Sean E. Browne
Mr. Sean E. Browne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mark A. Schallenberger
Mr. Mark A. Schallenberger
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jonn R. Beeson
Mr. Jonn R. Beeson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
6.21M
-7.87%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
593.73K
-2.78%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Kevin D. Brandt
Mr. Kevin D. Brandt
Chief Commercial Officer
Chief Commercial Officer
337.88K
+49.10%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
234.31K
-4.39%
Ms. Lori Mitchell-Keller
Ms. Lori Mitchell-Keller
Independent Director
Independent Director
190.96K
-8.17%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Orthobiologics
18.07M
54.93%
Spinal implant
11.21M
34.07%
License revenue
3.62M
11.00%
By RegionUSD
Name
Revenue
Proportion
United States
30.12M
91.53%
Rest of World
2.79M
8.47%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Orthobiologics
18.07M
54.93%
Spinal implant
11.21M
34.07%
License revenue
3.62M
11.00%
Shareholding Stats
Updated: Fri, Apr 18
Updated: Fri, Apr 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
49.09%
Lytton (Laurence W)
6.79%
Altium Capital Management LP
5.21%
Vizirgianakis (Stavros G)
4.46%
The Vanguard Group, Inc.
1.62%
Other
32.84%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
49.09%
Lytton (Laurence W)
6.79%
Altium Capital Management LP
5.21%
Vizirgianakis (Stavros G)
4.46%
The Vanguard Group, Inc.
1.62%
Other
32.84%
Shareholder Types
Shareholders
Proportion
Hedge Fund
49.67%
Individual Investor
14.69%
Investment Advisor/Hedge Fund
5.66%
Investment Advisor
2.21%
Research Firm
0.02%
Other
27.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
66
100.67M
72.26%
-8.91M
2025Q1
66
107.33M
77.15%
-2.25M
2024Q4
65
107.45M
77.30%
-1.32M
2024Q3
60
109.08M
78.63%
+8.43M
2024Q2
61
99.68M
76.50%
-1.69M
2024Q1
63
100.56M
77.45%
+777.79K
2023Q4
59
100.17M
77.23%
+1.05M
2023Q3
55
100.31M
77.56%
+9.94M
2023Q2
49
90.55M
83.28%
+1.27M
2023Q1
52
90.02M
82.83%
-239.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
68.39M
49.09%
+57.00M
+500.26%
Apr 10, 2025
Lytton (Laurence W)
9.46M
6.79%
+9.46M
--
Apr 15, 2025
Altium Capital Management LP
7.25M
5.21%
-162.41K
-2.19%
Mar 31, 2025
Vizirgianakis (Stavros G)
6.21M
4.46%
-530.88K
-7.87%
Feb 28, 2025
The Vanguard Group, Inc.
2.25M
1.62%
+100.60K
+4.68%
Mar 31, 2025
Browne (Sean E.)
1.51M
1.08%
+659.49K
+77.40%
Feb 28, 2025
Beeson (Jonn R.)
1.21M
0.87%
-16.98K
-1.38%
Feb 28, 2025
Renaissance Technologies LLC
711.21K
0.51%
-86.82K
-10.88%
Mar 31, 2025
Bakewell (John K)
593.73K
0.43%
-16.98K
-2.78%
Feb 28, 2025
McNamara (Robert E)
591.99K
0.42%
-16.98K
-2.79%
Feb 28, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI